MSC Therapy in GvHD & Fibrosis — PatSnap Eureka
Mesenchymal Stromal Cell Therapy in GvHD & Fibrotic Disease
Allogeneic MSC platforms — from bone marrow infusion to engineered EVs — are reshaping treatment options for steroid-refractory GvHD and organ fibrosis. Explore the full innovation pipeline with PatSnap Eureka.
GvHD and Fibrotic Disease: The Unmet Need Driving MSC Research
Graft-versus-host disease (GvHD) arises when donor-derived T lymphocytes recognize recipient alloantigens and mount an immune attack on host tissues following allogeneic hematopoietic stem cell transplantation. Both acute GvHD (aGvHD) and chronic GvHD (cGvHD) are characterized by dysregulated alloreactive T-cell activity, with cGvHD additionally involving pathogenic fibrosis — particularly in the skin, lung, and liver. Mast cells have been identified as mediators of fibrosis and effector cell recruitment in dermal cGvHD, with chemokine production as a druggable mechanism, and the CCL1 chemokine axis has been identified as a pathogenic mediator in sclerodermatous GVHD-associated pulmonary fibrosis.
Across fibrotic disease indications — spanning liver cirrhosis, pulmonary fibrosis, systemic sclerosis (SSc), and chronic kidney disease — the dominant molecular drivers include TGF-β1 signaling, IL-17A/IL-6/STAT3 inflammatory cascades, hepatic stellate cell (HSC) activation, extracellular matrix (ECM) accumulation, and oxidative stress pathways. In myelofibrosis, the alarmin complex S100A8/S100A9 marks disease progression in pro-fibrotic MSC subpopulations, as identified by Hannover Medical School researchers.
The allogeneic "off-the-shelf" paradigm is particularly significant given the urgent unmet need in steroid-refractory GvHD — where two-year mortality exceeds 80% — and the lack of effective disease-modifying therapies for organ fibrosis. According to data tracked by WHO and ClinicalTrials.gov, over 900 MSC clinical trials have been registered globally across all fields.
Six Allogeneic MSC Approaches Across GvHD and Fibrotic Disease
From regulatory-approved BM-MSC infusion to preclinical EV platforms, the pipeline spans a broad spectrum of cell-based and acellular strategies.
Allogeneic BM-MSC Infusion
Intravenous infusion of bone marrow-derived MSCs from allogeneic donors suppresses alloreactive T-cell proliferation, inhibits mixed lymphocyte reactions, and promotes regulatory T-cell phenotypes. Prochymal® (remestemcel-L) achieved product approval for pediatric steroid-refractory aGvHD in Canada and New Zealand. A Phase I study of allogeneic clonal MSCs (cMSCs) in 11 patients with refractory GvHD at Inha University / SCM Lifescience found an acceptable safety profile with a 27.3% serious adverse event rate.
Phase I–III · 1 Regulatory ApprovalUmbilical Cord-Derived MSCs (UC-MSCs)
UC-MSCs are a preferred allogeneic source due to high availability, low immunogenicity, and superior proliferative capacity. A pilot randomized study from Beijing 302 Hospital evaluated UC-MSC infusion (1×10⁶/kg) in 27 liver allograft recipients with acute rejection — 13 receiving UC-MSCs weekly for 10 weeks demonstrated liver function improvement without side effects at 12-week follow-up. A Phase I/IIa trial from Daewoong Pharmaceutical used intravenous allogeneic umbilical cord blood-derived MSCs in recessive dystrophic epidermolysis bullosa (RDEB) at 1×10⁶ to 3×10⁶ cells/kg across three infusions.
Phase I/IIa ClinicalMSC-Derived Extracellular Vesicles & Secretome
Cell-free alternatives including EVs, exosomes, microvesicles, and conditioned medium retain immunomodulatory and anti-fibrotic properties while avoiding tumorigenesis, uncontrolled differentiation, and cell rejection risks. EV preparations from adipose MSCs exerted superior anti-fibrotic activity versus parent cells in TGF-β1-induced myofibroblast models. IFNγ-primed MSC-EV preparations improved lung fibrosis in murine HOCl-induced SSc models. Tonsil-derived MSC small EVs reduced liver fibrosis through transfer of miR-486-5p.
Predominantly PreclinicalEngineered & Gene-Modified MSCs
Multiple genetic enhancement strategies improve MSC homing, engraftment, and potency. FasL-overexpressing MSCs (adenoviral) significantly enhanced immunomodulatory activity in murine aGvHD. HGF-overexpressing MSCs produced superior antifibrotic effects versus unmodified cells in rat liver fibrosis. CCR2-overexpressing MSCs (lentiviral) improved homing in acute liver failure (ALF) models, as the CCL2/CCR2 axis is highly upregulated in damaged liver. Lentiviral c-Met overexpression improved homing via the HGF/c-Met axis.
Predominantly PreclinicalPreconditioned / Primed MSCs
Preconditioning prior to administration enhances viability, homing, and immunomodulatory potency. Cytokine pretreatment strategies include IL-1β (enhances CXCR4 expression, improving homing to ALF-injured liver), HGF, FGF4, and IFNγ. An injectable self-healing hydrogel scaffold was developed for MSC delivery in systemic sclerosis to improve persistence and engraftment in vivo, addressing the short persistence and poor engraftment of intravenously delivered MSCs.
PreclinicalhESC-Derived MSC-Like Cells (IMRCs)
Immunity- and matrix-regulatory cells (IMRCs) are a GMP-compliant human embryonic stem cell-derived product with a gene expression profile distinct from UC-MSCs — exhibiting higher levels of proliferative, immunomodulatory, and anti-fibrotic genes. Intravenous delivery of IMRCs inhibited pulmonary inflammation and fibrosis in mouse models, signaling movement toward standardized, scalable, GMP-grade allogeneic cell products with defined and superior gene expression profiles.
Early TranslationalKey Molecular Targets in MSC-Based Therapy
Patent and literature analysis via PatSnap Eureka reveals five dominant target axes driving MSC therapeutic development across GvHD and fibrotic disease indications.
Therapeutic Modality Coverage by Indication
Distribution of MSC modalities across GvHD and fibrotic disease indications — GvHD and liver fibrosis show the broadest modality coverage.
Molecular Target Pathway Activity
Evidence density for five key molecular axes targeted by MSC therapies across GvHD and fibrotic disease indications in the retrieved dataset.
Clinical Trial Landscape: GvHD and Fibrotic Disease
Retrieved results contain multiple explicit clinical signals across GvHD and fibrotic disease indications, from Phase I safety studies to regulatory approvals.
Track 900+ MSC Clinical Trials in Real Time
PatSnap Eureka aggregates patent and literature signals to surface clinical-stage intelligence faster.
Combination Approaches & Next-Generation Strategies
Retrieved results signal six combination and emerging strategies that may define the next wave of MSC-based therapeutic development.
MSCs + Small Molecules (Anti-Fibrotic Combination)
BM-MSC therapy combined with an anti-fibrotic agent can overcome renal fibrosis-mediated impairment of transplanted MSC viability in CKD, suggesting pre-treatment of the fibrotic microenvironment as a strategy to enhance MSC function (Monash University, 2022). A combination of BMSCs with ferulic acid showed superior efficacy over monotherapy in CCl4-induced rat liver fibrosis (Capital Medical University, 2022).
IFNγ-Primed MSC-EV Manufacturing
IFNγ pre-activation of MSCs before EV harvest substantially improves EV anti-fibrotic activity in SSc lung models, representing a manufacturing process innovation. IFNγ-primed MSC-EV preparations improved lung fibrosis in murine HOCl-induced SSc models (CHU Montpellier, 2021), positioning IFNγ priming as a key process variable for EV product development.
Engineered MSC + Chemokine Receptor Axis Targeting
CCR2 and CXCR4/SDF-1α axis engineering to improve homing is an active direction, with controlled-release microspheres for SDF-1α delivery also being explored (Medical University of Silesia, 2022). The CCL2/CCR2 axis is highly upregulated in damaged livers, making it a rational engineering target for hepatic indications.
Combinatorial Immunotherapy for cGvHD
MSCs are being evaluated alongside T regulatory cells, CAR-T cells, NK cells, and innate lymphoid cells for prophylaxis and treatment of cGvHD, signaling that single-modality cell therapy may evolve into combinatorial immunotherapy regimens (Ludwig Boltzmann Institute, Vienna, 2022). This positions MSCs as a component within multi-cellular therapeutic platforms.
Key Institutions & Commercial Entities in the MSC Pipeline
Innovation activity in this dataset is dominated by academic medical centers and research hospitals, with a smaller number of commercial entities represented. The dataset is entirely literature-driven; no patent filings were retrieved in this search layer, indicating that IP activity requires a separate patent-specific search strategy via PatSnap's analytics platform.
Commercial entities with product-level signals include ReGenesys (Belgium) / Osiris Therapeutics with the MultiStem®/Prochymal® platform — the furthest clinical translation signal in this dataset — SCM Lifescience Co., Ltd. / Inha University (Korea) with Phase I allogeneic clonal MSC for refractory GvHD, and Daewoong Pharmaceutical Co. Ltd. (Seoul, Korea) with Phase I/IIa allogeneic hUCB-MSC for RDEB.
Academic centers with highest publication density include Montpellier / INSERM U1183 (France) — multiple papers on MSC-EVs and ASC-EVs in systemic sclerosis fibrosis models and IFNγ priming strategies — and Chinese Academy of Sciences / affiliated hospitals with broad coverage of MSC therapy in liver fibrosis, ALF, and GvHD engineering strategies. The life sciences innovation landscape also features contributions from MD Anderson Cancer Center, Mayo Clinic, Massachusetts General Hospital / Harvard Medical School, and The Prince Charles Hospital / Queensland (Australia) for the first-in-man CLAD study. HLA mismatch assessment is highlighted as critical for off-the-shelf allogeneic product design, as flagged by European Bioinformatics Institute and Jagiellonian University researchers.
Strategic Implications for MSC Therapy Development
Four critical strategic findings from the patent and literature dataset with direct implications for R&D and commercial development decisions.
MSC Homing Engineering Strategies
Four receptor-axis engineering approaches identified to improve MSC engraftment — poor in vivo homing is a key limitation of current MSC therapies.
MSC-EV Platform: Strategic Differentiation Signals
Key advantages of acellular MSC-EV products over intact MSC transplantation in fibrosis models, positioning EVs as a strategically differentiated IP direction.
Mesenchymal Stromal Cell Therapy in GvHD & Fibrosis — key questions answered
Prochymal® (remestemcel-L) has received product approval for pediatric steroid-refractory acute GvHD in Canada and New Zealand, representing the furthest clinical translation signal in this dataset. Phase I and Phase III studies have been referenced for MSC treatment of GvHD, and a Phase I allogeneic clonal MSC study in 11 patients with refractory GvHD post allo-HSCT found an acceptable safety profile with a 27.3% serious adverse event rate. Phase III efficacy in adult GvHD remains unestablished.
MSC-derived EV and secretome platforms are positioned as potentially superior to intact MSC transplantation in fibrosis models, particularly in systemic sclerosis, with reduced safety concerns including no tumorigenesis and no allogeneic rejection, and potentially scalable manufacturing. EV preparations from adipose tissue-derived MSCs were found to exert superior anti-fibrotic activity compared to parent cells in TGF-β1-induced myofibroblast models.
Across retrieved results, the dominant molecular drivers of fibrosis include TGF-β1 signaling, IL-17A/IL-6/STAT3 inflammatory cascades, hepatic stellate cell activation and extracellular matrix accumulation, and oxidative stress pathways. MSC-based therapies — both cellular and acellular — are reported to suppress TGF-β1-induced myofibroblast activation and ECM accumulation.
Cell heterogeneity and inconsistent therapeutic outcomes remain the primary translational bottleneck. MSC heterogeneity — compounded by variable tissue sources including bone marrow, umbilical cord, adipose, placenta, tonsil, and liver, as well as culture conditions and donor variability — is identified as the root cause of mixed clinical results, motivating clonal MSC selection methods, GMP standardization, and shift toward defined cell-free secretome and EV products.
CCR2 overexpression via lentiviral transduction significantly improves targeted engraftment in damaged liver, as the CCL2/CCR2 axis is highly upregulated in damaged livers. CXCR4 upregulation via IL-1β pretreatment similarly improves liver homing. Lentiviral c-Met overexpression in BMSCs improved homing to ALF-injured liver via the HGF/c-Met axis.
Retrieved results flag that allogeneic MSCs are not universally immune-privileged. TLR7 agonist stimulation can increase MSC immunogenicity, and HLA mismatch assessment is highlighted as critical for off-the-shelf allogeneic product design.
Still have questions? Let PatSnap Eureka answer them for you.
Ask PatSnap Eureka About MSC TherapyAccelerate Your MSC Therapy Research with AI-Powered Innovation Intelligence
Join 18,000+ innovators already using PatSnap Eureka to navigate the GvHD and fibrosis cell therapy pipeline — from molecular targets to clinical signals and assignee landscapes.
References
- Mast Cells Are Mediators of Fibrosis and Effector Cell Recruitment in Dermal Chronic Graft-vs.-Host Disease — University of Kentucky (2019)
- CCL1 blockade alleviates hMSC-induced pulmonary fibrosis in a murine sclerodermatous GvHD model — Seoul St. Mary's Hospital (2020)
- Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis — Hannover Medical School (2021)
- Extracellular Vesicles Are More Potent Than Adipose Mesenchymal Stromal Cells to Exert an Anti-Fibrotic Effect in an In Vitro Model of Systemic Sclerosis — University of Montpellier / INSERM U1183 (2021)
- Allogeneic clonal mesenchymal stem cell therapy for refractory graft-versus-host disease: a phase I study — Inha University / SCM Lifescience (2016)
- Application of MultiStem® Allogeneic Cells for Immunomodulatory Therapy: Clinical Progress and Pre-Clinical Challenges — ReGenesys, Belgium (2012)
- Mesenchymal Stromal Cell Therapy for Chronic Lung Allograft Dysfunction: Results of a First-in-Man Study — The Prince Charles Hospital, Brisbane (2017)
- A Pilot Study of Mesenchymal Stem Cell Therapy for Acute Liver Allograft Rejection — Beijing 302 Hospital (2017)
- Intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients — Daewoong Pharmaceutical (2021)
- Lung Fibrosis Is Improved by Extracellular Vesicles from IFNγ-Primed Mesenchymal Stromal Cells in Murine Systemic Sclerosis — CHU Montpellier (2021)
- sEVs from tonsil-derived mesenchymal stromal cells alleviate activation of hepatic stellate cells and liver fibrosis through miR-486-5p — Pusan National University (2021)
- Mesenchymal Stem Cell-Derived Molecules Reverse Fulminant Hepatic Failure — Massachusetts General Hospital / Harvard Medical School (2007)
- Treatment with Mesenchymal Stromal Cells Overexpressing Fas-Ligand Ameliorates Acute Graft-versus-Host Disease in Mice — "Nicolae Simionescu" Institute, Bucharest (2022)
- Therapeutic effect of hepatocyte growth factor-secreting mesenchymal stem cells in a rat model of liver fibrosis — Ajou University (2014)
- CCR2-overexpressing mesenchymal stem cells targeting damaged liver enhance recovery of acute liver failure — Third Affiliated Hospital, Sun Yat-sen University (2022)
- Overexpression of c-Met in bone marrow mesenchymal stem cells improves their effectiveness in homing and repair of acute liver failure — Anhui Provincial Hospital (2017)
- IL-1β Pretreatment Improves the Efficacy of Mesenchymal Stem Cells on Acute Liver Failure by Enhancing CXCR4 Expression — Wuxi People's Hospital (2020)
- MSCs-laden injectable self-healing hydrogel for systemic sclerosis treatment — Macau University of Science and Technology (2022)
- Immunity-and-Matrix-Regulatory Cells Derived from Human Embryonic Stem Cells Safely and Effectively Treat Mouse Lung Injury and Fibrosis — National Center for Safety Evaluation of Drugs, China (2020)
- Bone marrow-derived stem cells ameliorate hepatic fibrosis by down-regulating interleukin-17 — Fourth Military Medical University (2013)
- Bone marrow derived-mesenchymal stem cells downregulate IL17A dependent IL6/STAT3 signaling pathway in CCl4-induced rat liver fibrosis — Cairo University (2018)
- The Importance of HLA Assessment in "Off-the-Shelf" Allogeneic Mesenchymal Stem Cells Based-Therapies — Jagiellonian University (2019)
- Mesenchymal Stromal Cells for Graft Versus Host Disease: Mechanism-Based Biomarkers — King's College London (2020)
- Enhancing the Therapeutic Potential of Mesenchymal Stromal Cell-Based Therapies with an Anti-Fibrotic Agent for the Treatment of Chronic Kidney Disease — Monash University (2022)
- Ferulic Acid Combined With Bone Marrow Mesenchymal Stem Cells Attenuates the Activation of Hepatic Stellate Cells and Alleviates Liver Fibrosis — Capital Medical University (2022)
- Controlled Release of Encapsuled Stromal-Derived Factor 1α Improves Bone Marrow Mesenchymal Stromal Cells Migration — Medical University of Silesia (2022)
- Cell-based therapy in prophylaxis and treatment of chronic graft-versus-host disease — Ludwig Boltzmann Institute, Vienna (2022)
- PubMed — National Library of Medicine, NIH
- ClinicalTrials.gov — U.S. National Library of Medicine
- European Bioinformatics Institute (EMBL-EBI)
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.